India News

STF‑FDA Joint Raid Uncovers Counterfeit Drug Ring From Himachal’s Badri to Uttar Pradesh and Bihar

· GlobeWire Daily Editorial Desk · Source: www.amarujala.com

3 min read

STF‑FDA Joint Raid Uncovers Counterfeit Drug Ring From Himachal’s Badri to Uttar Pradesh and Bihar
Amar Ujala · resized and padded · Photo source

Summary

A coordinated operation by the Special Task Force (STF) and the Food Safety and Drug Administration (FDA) busted a large counterfeit‑medicine network that manufactured fake tablets in Badri, Himachal Pradesh and shipped them to Uttar Pradesh and Bihar. The gang reportedly produced pills for ₹20‑₹25 using chalk‑powder, sold them to middlemen for ₹300‑₹350 per box, and retailed the counterfeit products at genuine market rates of ₹1,800‑₹2,300.

Details of the raid

  • Location of factories: Three illegal drug‑making units were sealed in Badri, Himachal. One was run by a local named Sunil Kumar, who had no manufacturing licence and allegedly bought equipment from a closing factory. Another unit possessed a purchase‑license but no production licence; the third is still under investigation.
  • Key arrests: STF detained three suspects – Abhishek Singh, Haseen (a broker), and Monu Kumar. They are accused of coordinating the supply chain from Badri to dealers in Uttar Pradesh and Bihar. Several other alleged accomplices, including Haseen’s brother Vaseem, Pankaj and Sunil, remain at large.
  • Drug types and pricing: The counterfeit stock included brands such as Pan‑40 (market price ≈ ₹1,900 per strip) and Neurokind LC (≈ ₹2,300 per strip). The gang bought these fake boxes for roughly ₹300 per box and sold them at authentic prices, generating a large profit margin.
  • Operational method: According to STF interrogations, the gang mixed chalk‑powder with other inexpensive fillers to mimic real tablets. The low production cost (₹20‑₹25) allowed them to earn thousands of rupees per batch.

Official statements and next steps

  • STF spokesperson said the raid was the result of months of surveillance and that “the network exploited weak inter‑state monitoring, moving counterfeit medicines across state borders without detection.”
  • FDA officials emphasized that the seized products are unsafe and urged pharmacies and consumers to verify drug licences before purchase.
  • Investigations continue to locate the alleged mastermind and additional members of the syndicate. Further arrests are expected as STF expands its inquiry into linked individuals in both Himachal and western Uttar Pradesh.

Practical implications for the public

  • Check authenticity: Consumers should inspect packaging, batch numbers, and verify licences on the FDA portal.
  • Report suspicious drugs: Any pharmacy or individual suspecting counterfeit medicines can contact the local FDA office or STF helpline.
  • Stay informed: Follow updates from reputable news outlets and official agency releases for any new developments.

How to verify the original announcement

  • The STF press release dated Thursday, 21 Nov 2026 is available on the Himachal Police website.
  • FDA’s joint statement can be accessed through the FDA’s official newsroom.
  • Both agencies have posted briefings on their verified Twitter handles.

--- Keywords: ["counterfeit drug raid", "STF FDA joint operation", "Badri Himachal drug factory", "fake Pan‑40", "Neurokind LC counterfeit", "₹20‑₹25 production cost", "inter‑state drug smuggling", "Uttar Pradesh Bihar counterfeit medicines"]

Share this article

About the author

GlobeWire Daily Editorial Desk

More to read